Motolimod / VTX2337

Target: Toll-Like Receptor | Disease State: Cancer

Introduction / Brief Description

Motolimod is a small-molecule agonist of toll-like receptor 8 invented by Array and licensed to VentiRx. Array received equity in VentiRx, as well as an up-front payment and the right to receive potential milestone payments and royalties on product sales. To date, Array has received $2.6 million in milestone payments and has the potential to earn $56 million if the program achieves the remaining clinical and commercial milestones under the agreement. In February 2017, Celgene acquired VentiRx and the motolimod program.

Motolimod is designed to mobilize a patient's immune system by directly activating myeloid dendritic cells, monocytes and natural killer cells. This activation results in the production of a high level of mediators known to orchestrate the integration of both the innate and adaptive anti-tumor responses to a number of cancers. The addition of motolimod to some standard-of-care anticancer agents (chemotherapy, monoclonal antibodies) may dramatically augment the anti-tumor response. Early data from an ongoing Phase 1 trial in squamous cell carcinoma of the head and neck demonstrated that the combination was safe and well tolerated, and demonstrated activation of natural killer cells following dosing with motolimod. Two randomized Phase 2 trials in ovarian cancer and head and neck cancer are currently enrolling patients.

Clinical Trials 

To learn more about motolimod clinical trials, click here.

Publications and Presentations



Clinical Cancer Research

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC

H. Lu, et al

To view all publications, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.